Monday 19 March 2012

Cancer News-News Wires-Research

J&J unblind Zytiga phase 3 trial in pre-chemotherapy castrate-resistant prostate cancer

The big cancer news that hit the news wires this morning was not entirely surprising: “Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA (abiraterone acetate) plus prednisone for the treatment of … Continue reading ? read more..

No comments:

Post a Comment